MINNEAPOLIS & BARCELONA, Spain--(BUSINESS WIRE)--Today at EuroPCR, Medtronic, Inc. (NYSE: MDT), released four-year data from the ENDEAVOR II clinical trial that reinforces the long-term safety and durable efficacy of the company’s Endeavor Zotarolimus-Eluting Coronary Stent System for the treatment of coronary artery disease.
